


Searching News Database: Seizure
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 2 Apr 2026
Zeto Announces FDA 510(k) Clearance of Zeto New Wave(TM), Advancing Efficiency in Outpatient EEG
Zeto Announces FDA 510(k) Clearance of Zeto New Wave(TM), Advancing Efficiency in Outpatient EEG
HSMN NewsFeed - 17 May 2023
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
HSMN NewsFeed - 15 Feb 2023
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
HSMN NewsFeed - 24 Aug 2022
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 8 Nov 2021
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Eprontia(TM) (Topiramate) Oral Solution
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Eprontia(TM) (Topiramate) Oral Solution
HSMN NewsFeed - 1 Jun 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
HSMN NewsFeed - 29 Jul 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
HSMN NewsFeed - 16 Apr 2019
Cerebral Therapeutics Strengthens Clinical Development Leadership with Strategic Appointments
Cerebral Therapeutics Strengthens Clinical Development Leadership with Strategic Appointments
HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
HSMN NewsFeed - 17 Aug 2018
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 29 May 2018
Zeto Announces First Dry Electrode, Wireless EEG Headset Approved by FDA for Clinical Use
Zeto Announces First Dry Electrode, Wireless EEG Headset Approved by FDA for Clinical Use
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 5 May 2017
Ram Group Announces Breakthrough in Non-Invasive Cardio-Pulmonary Monitoring Wearables
Ram Group Announces Breakthrough in Non-Invasive Cardio-Pulmonary Monitoring Wearables
HSMN NewsFeed - 25 Apr 2017
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
HSMN NewsFeed - 27 Jan 2017
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
HSMN NewsFeed - 22 Mar 2016
First FDA-Approved Medicine Manufactured Using 3D Printing Technology Now Available
First FDA-Approved Medicine Manufactured Using 3D Printing Technology Now Available
HSMN NewsFeed - 22 Mar 2016
Nihon Kohden Debuts Breakthrough in Neuromonitoring Remote Access with Live View Panel
Nihon Kohden Debuts Breakthrough in Neuromonitoring Remote Access with Live View Panel
HSMN NewsFeed - 24 Feb 2016
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
HSMN NewsFeed - 15 Jan 2016
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 1 Dec 2015
Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 19 Aug 2014
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
HSMN NewsFeed - 15 Jul 2014
Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices
Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices
HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
HSMN NewsFeed - 28 Apr 2014
Cyberonics Names Rohan Hoare, Ph.D. Chief Operating Officer And O'Neill D'Cruz, M.D. Chief Medical Officer
Cyberonics Names Rohan Hoare, Ph.D. Chief Operating Officer And O'Neill D'Cruz, M.D. Chief Medical Officer
HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
HSMN NewsFeed - 20 Feb 2014
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy(R)
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy(R)
HSMN NewsFeed - 3 Jan 2014
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 15 Nov 2013
Wright Medical Group, Inc. Completes Acquisition of Biotech International
Wright Medical Group, Inc. Completes Acquisition of Biotech International
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 16 Oct 2013
Wright Medical Group, Inc. Announces Definitive Agreement to Acquire Biotech International
Wright Medical Group, Inc. Announces Definitive Agreement to Acquire Biotech International
HSMN NewsFeed - 21 Aug 2013
Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
HSMN NewsFeed - 19 Aug 2013
Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
HSMN NewsFeed - 21 May 2013
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 1 Mar 2013
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
HSMN NewsFeed - 26 Feb 2013
FDA Advisory Panel Recommends Approval of the NeuroPace RNS(R) System for Medically Refractory Epilepsy
FDA Advisory Panel Recommends Approval of the NeuroPace RNS(R) System for Medically Refractory Epilepsy
HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
HSMN NewsFeed - 10 Jan 2013
Alere Executes License Agreement with Miraculins for Preeclampsia Technology
Alere Executes License Agreement with Miraculins for Preeclampsia Technology
HSMN NewsFeed - 7 Jan 2013
RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals
RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals
HSMN NewsFeed - 19 Nov 2012
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses
HSMN NewsFeed - 4 Sep 2012
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
HSMN NewsFeed - 2 Apr 2012
UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma
UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma
HSMN NewsFeed - 15 Mar 2012
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
HSMN NewsFeed - 3 Jan 2012
Cyberonics Announces FDA Approval of Re-Designed AspireHC(TM) Generator for VNS Therapy
Cyberonics Announces FDA Approval of Re-Designed AspireHC(TM) Generator for VNS Therapy
HSMN NewsFeed - 19 Sep 2011
Wright Medical Group, Inc. Names Robert J. Palmisano President and Chief Executive Officer
Wright Medical Group, Inc. Names Robert J. Palmisano President and Chief Executive Officer
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
HSMN NewsFeed - 14 Jun 2011
CerebralRx Enters Global Neuromodulation Market With the FitNeS(TM) System for Treating Epilepsy
CerebralRx Enters Global Neuromodulation Market With the FitNeS(TM) System for Treating Epilepsy
HSMN NewsFeed - 13 Jun 2011
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
HSMN NewsFeed - 1 Feb 2011
Cyberonics Announces FDA Approval of Aspire High Capacity Generator for VNS Therapy
Cyberonics Announces FDA Approval of Aspire High Capacity Generator for VNS Therapy
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 16 Sep 2010
Medtronic Receives European CE Mark Approval for Deep Brain Stimulation Therapy for Refractory Epilepsy
Medtronic Receives European CE Mark Approval for Deep Brain Stimulation Therapy for Refractory Epilepsy
HSMN NewsFeed - 8 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 7 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 30 Mar 2010
Philips Launches New Endovascular Therapeutic Hypothermia System To Help Enhance Patient Care
Philips Launches New Endovascular Therapeutic Hypothermia System To Help Enhance Patient Care
HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
HSMN NewsFeed - 7 Dec 2009
Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 21 Oct 2009
CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women
CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 10 Sep 2009
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
HSMN NewsFeed - 9 Sep 2009
Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
HSMN NewsFeed - 25 Aug 2009
CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter
CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter
HSMN NewsFeed - 29 Jul 2009
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
HSMN NewsFeed - 1 Jun 2009
FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
HSMN NewsFeed - 11 May 2009
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
HSMN NewsFeed - 17 Apr 2009
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
HSMN NewsFeed - 2 Apr 2009
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
HSMN NewsFeed - 27 Mar 2009
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 18 Dec 2008
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
HSMN NewsFeed - 16 Dec 2008
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
HSMN NewsFeed - 17 Oct 2008
Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine
Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 25 Sep 2008
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
HSMN NewsFeed - 24 Sep 2008
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
HSMN NewsFeed - 16 Jul 2008
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 29 May 2008
StemCells Confirms Previously Reported Batten Trial Death Was Due to Natural Progression of Disease
StemCells Confirms Previously Reported Batten Trial Death Was Due to Natural Progression of Disease
HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 8 May 2008
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
HSMN NewsFeed - 16 Apr 2008
Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression
Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression
HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
HSMN NewsFeed - 31 Mar 2008
Medtronic Insertable Heart Monitor Gives New Insight Into Common Heart Rhythm Disturbance
Medtronic Insertable Heart Monitor Gives New Insight Into Common Heart Rhythm Disturbance
HSMN NewsFeed - 19 Mar 2008
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 8 Mar 2008
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
HSMN NewsFeed - 11 Feb 2008
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
HSMN NewsFeed - 26 Dec 2007
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
HSMN NewsFeed - 12 Dec 2007
Medtronic Implantable Cardiac Monitors Give Physicians Valuable Insights into Heart Rhythms
Medtronic Implantable Cardiac Monitors Give Physicians Valuable Insights into Heart Rhythms
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 11 Dec 2007
Cyberkinetics Receives FDA Response Letter on Andara(TM) OFS(TM) System for Acute Spinal Cord Injury
Cyberkinetics Receives FDA Response Letter on Andara(TM) OFS(TM) System for Acute Spinal Cord Injury
HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
HSMN NewsFeed - 27 Nov 2007
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 12 Nov 2007
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
HSMN NewsFeed - 8 Nov 2007
Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy
Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 23 Oct 2007
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Additional items found! 336
Members Archive contains
336 additional stories matching:
Seizure
(Password required)
Seizure
(Password required)
